Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 25 Mar 2024
Ever since the FDA withdrew Evusheld's authorization last year, there hasn't been a similar choice.
Read Full NewsThe World Health Organization on Friday urged governments to do more to control the sale of nicotine pouches, warning that the highly addictive products were being...
Across 273 requests for chest CTs for incidental lung findings on neck imaging, only one indolent lung cancer was detected.
The approval of IV atezolizumab and atezolizumab with hyaluronidase-tqjs is the first for bladder cancer since a 2022 withdrawal of accelerated approval of atezolizumab for urothelial carcinoma.
1.
Five new papers highlight cancer inequities, challenges and opportunities in South Asia
2.
Prostate cancer screening program beneficial in top decile of polygenic risk score
3.
How a new light-based cancer treatment could destroy tumors without harming healthy cells—using LEDs
4.
Ineffective medication can remove the "worst fear" of schizophrenia.
5.
Aspirin for CRC Risk Reduction May Benefit Unhealthy People Most
1.
Harnessing Artificial Intelligence in Oncology: Innovations in Diagnosis, Treatment, and Patient Care
2.
Personalized Neoantigen Vaccines and the Promise of a Less Toxic Future in Pediatric Oncology
3.
The Oncologist’s Edge: Tools, Trials, and Tech Transforming Treatment
4.
The New Era of Oncology: Key Updates and Clinical Insights
5.
What Is Carboxyhemoglobin And How Can It Affect Your Health?
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Efficient Management of First line ALK-rearranged NSCLC - Part IV
2.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part III
3.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- The Conclusion
4.
Current Scenario of Blood Cancer- Genomic Testing & Advancement in Diagnosis and Treatment
5.
Understanding Early Relapse in B-cell ALL: Rates, Risks, and Common Sites
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge